PharmExec

CONTINUE TO SITE

OR WAIT null SECS

Advertisement

Pharmaceutical Executive APEX Awards Latest Executive Roundtables

Pharmaceutical Executive APEX Awards Latest Executive Roundtables

View More DE&I Executive Profiles Sales and Marketing Strategy Technology

DE&IExecutive ProfilesSales and MarketingStrategyTechnology

Editorial Podcasts Editorial Videos

Conference Coverage Conference Listing

Pharmaceutical Executive

E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers

E-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

EnewsMagazine

Advertise
Contact Editorial
Editorial Submission Guidelines
Contact MJH Life Sciences
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.

Spotlight

Pharmaceutical Executive APEX Awards
Latest Executive Roundtables

DE&I
Executive Profiles
Sales and Marketing
Strategy
Technology

Advertise
Contact Editorial
Editorial Submission Guidelines
Contact MJH Life Sciences
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

© 2023 MJH Life Sciences^™ and Pharmaceutical Executive. All rights reserved.

Robert L. Stoll

home

Articles

Attacks on Pharmaceutical Improvement Patents

Pharmaceutical Executive

Is Congress harming pharmaceutical research by limiting enforcement of improvement patents?